ReviewCurrent opinion in allergy and clinical immunology2013
The ocular surface epithelial barrier and other mechanisms of mucosal protection: from allergy to infectious diseases.
Review in Current opinion in allergy and clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 129 citations in OpenAlex.
- Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model.Bioengineering (Basel, Switzerland) · 2026Article
- Development of Human Conjunctival Goblet Cell Segmentation Datasets to Improve Quantitation.Scientific data · 2026Article
- Core-shell nanotherapeutics for diabetic cataract and retinopathy: current state-of-the-art and translational challenges.Drug delivery and translational research · 2026Review
- Ocular Surface Microbiota Alterations Following FS-LASIK and Their Association With Postoperative Dry Eye.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Emerging mechanisms in dry eye disease: apoptosis-associated tear MicroRNAs and toxicant-related alterations of the glycocalyx and lipid rafts.Frontiers in ophthalmology · 2026Article
- Identification of dysregulated gene clusters and pathways driving ocular surface squamous neoplasia progression.Scientific reports · 2025Article
- Recent advances in engineered exosome-based therapies for ocular vascular disease.Journal of nanobiotechnology · 2025Review
- Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing.Pharmaceutics · 2025Article
- ThemBio · 2025Article
- Recent Advances in Smart Polymers-Based Therapeutics in Ophthalmology.International journal of nanomedicine · 2025Review
- The role of epithelial membrane-associated mucin 4 in ocular surface health and corneal wound healing.Frontiers in medicine · 2025Article
- Article
- Ephrin-Eph signaling: an important regulator of epithelial integrity and barrier function.Tissue barriers · 2025Review
- Review
- The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis.Clinical microbiology reviews · 2024Review
- Allergic Conjunctivitis: Review of Current Types, Treatments, and Trends.Life (Basel, Switzerland) · 2024Review
- Selective Upregulation of Interleukin 1 Receptor Antagonist and Interleukin-8 in Fuchs' Endothelial Corneal Dystrophy with Accompanying Cataract.Journal of clinical medicine · 2024Article
- Protective Effect of Probiotics againstInternational journal of molecular sciences · 2024Article
- Selective Bowman's layer transplantation in the treatment of neurotrophic corneal ulcers.Indian journal of ophthalmology · 2024Article
- A nerve-goblet cell association promotes allergic conjunctivitis through rapid antigen passage.JCI insight · 2023Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewStudies completed in the last decade provide new insights into the role of the epithelial glycocalyx in maintaining ocular surface barrier function. This review summarizes these findings, their relevance to allergic and infectious disease, and highlights the potential benefits of exploiting the modulation of barrier integrity for therapeutic gain. RECENT
findingsThe molecular components sealing the space between adjacent ocular surface epithelial cells, such as tight junctions, have been extensively characterized, and their contribution to the paracellular barrier established. A second layer of protection - the transcellular barrier - is provided by transmembrane mucins and their O-glycans on the glycocalyx. Cell surface glycans bind carbohydrate-binding proteins to promote formation of complexes that are no longer thought to be a static structure, but, instead, a dynamic system that responds to extrinsic signals and modulates pathogenic responses. Although functioning as a protective mechanism to maintain homeostasis, the glycocalyx also restricts drug targeting of epithelial cells. SUMMARY: The traditional model of intercellular junctions protecting the ocular surface epithelia has recently been expanded to include an additional glycan shield that lines apical membranes on the ocular surface. A better understanding of this apical barrier may lead to better management of ocular surface disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.